1Division of Gastroenterology, Calgary General Hospital, Alta.
Treatment for inflammatory bowel disease (IBD) is expanding, with options chosen based on disease severity. Newer 5-aminosalicylic acid (5-ASA) compounds and other therapies offer improved management for ulcerative colitis and other IBD conditions.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: